Johnson & Johnson Reports Q3 2026 Results and Raises Full-Year Guidance

Executive Summary

On October 13, 2026, Johnson & Johnson (NYSE: JNJ) filed a Form 8-K under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), announcing financial results for the third quarter ended September 27, 2026, and increasing full-year 2026 financial guidance.

---

Key Financial Metrics (Q3 2026 vs. Q3 2025)

• Total Reported Sales: $25,399 million vs. $23,993 million (+5.9% reported, +6.0% operational, +6.1% adjusted operational).
• GAAP Net Earnings: $210 million vs. $5,152 million (-95.9%).
• GAAP Diluted EPS: $0.09 vs. $2.12 (-95.8%), heavily impacted by special items, including a one-time charge for proposed talc litigation resolution, the Firefly Bio, Inc. acquisition, and the strategic collaboration with Sail Biomedicines.
• Adjusted Net Earnings: $6,339 million vs. $6,801 million (-6.8%).
• Adjusted Diluted EPS: $2.59 vs. $2.80 (-7.5%).
• Free Cash Flow (YTD): ~$15.1 billion compared to $14.2 billion in prior year period.

---

Segment Performance

1. Innovative Medicine:
   • Sales: $16,757 million (+7.7% reported, +7.9% operational, +8.0% adjusted operational).
2. MedTech:
   • Sales: $8,642 million (+2.5% reported, +2.5% operational, +2.5% adjusted operational).

Geographic Performance

• U.S. Sales: $14,959 million (+9.1% YoY).
• International Sales: $10,440 million (+1.5% reported, +1.8% operational).

---

FY 2026 Guidance Update

• Reported Sales: Increased to an estimated $101.2 billion (representing 7.4% growth at the midpoint).
• Adjusted Diluted EPS: Raised by $0.06 to $11.10 (representing 2.9% growth at the midpoint).

---

Strategic & Pipeline Highlights

• Secured market authorization for OTTAVA, introduced as the world's first table-integrated soft tissue robotic surgical system.
• Obtained regulatory approval for IMAAVY in warm autoimmune hemolytic anemia (wAIHA).
• Granted Priority Review for RYBREVANT FASPRO targeting advanced head and neck cancer.